News
Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...
For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...
3h
Investor's Business Daily on MSNThe Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.'
Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety ...
The Food and Drug Administration won’t sign off on Sarepta Therapeutics Inc. bringing its controversial gene therapy back to the market until the company can persuade US regulators that it won’t cause ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results